Document Classification

Section Type: RESULTS

Text: In the CRYSTAL and OPUS trials, respectively, the cutoff value of ETS 20 % (v < 20 %) identified patients with KRAS wild-type mCRC receiving chemotherapy plus cetuximab with longer PFS (medians 14. 1 v 7. 3 months, hazard ratio [HR] = 0. 32 ; P <. 001, and medians 11. 9 v 5. 7 months, HR = 0. 22 ; P <. 001) and survival (medians 30. 0 v 18. 6 months, HR = 0. 53 ; P <. 001 and medians 26. 0 v 15. 7 months, HR = 0. 43 ; P =. 006).